A study of ABO-202 for patients with infantile neuronal ceroid lipofuscinosis.

Trial Profile

A study of ABO-202 for patients with infantile neuronal ceroid lipofuscinosis.

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs ABO 202 (Primary)
  • Indications Neuronal ceroid lipofuscinosis
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Oct 2016 New trial record
    • 21 Sep 2016 According an Abeona Therapeutics media release, this trial anticipates to initiate in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top